Microdiversity Predicts Outcome in Children's Kidney Cancer
By LabMedica International staff writers Posted on 08 Feb 2015 |

Image: CT Scan of 11-centimeter Wilms' tumor of the right kidney in a 13-month-old patient (Photo courtesy of Wikimedia Commons).
A prognosis for the outcome of Wilms' tumor, the most common type of kidney cancer in children, can be determined by examining the genetic variation in a biopsy specimen as small as one millimeter in diameter.
Investigators at Lund University (Sweden) have termed genetic variation in such minute samples as microvariation or microdiversity. They established the importance of this type of variation by analyzing millimeter sized specimens from 44 cases of Wilms' tumor. All 44 patients had been treated with chemotherapy and while most recovered, a few—whose cancers demonstrated the greatest genetic variation between cells—developed metastases and died. Survival was 100% for patients lacking microdiversity.
Very few markers have been found in childhood kidney cancer that can differentiate between aggressive and less dangerous cancers. "The reason for this is that researchers have been looking for certain characteristics, such as mutations, in a single sample from each patient. However, when there is so much variation between the cells, one sample is not enough to determine the properties of the tumor," said senior author Dr. David Gisselsson, a researcher in clinical genetics at Lund University. "Tumors in children are also genetically unstable, and the greater the variation between the cells, the more malignant the cancer. The microvariation is a much better predictor of the risk of metastasis and death than the presence of individual mutations. This is an entirely new way of assessing how dangerous a tumor is."
The study was published in the January 27, 2015, online edition of the journal Nature Communications.
Related Links:
Lund University
Investigators at Lund University (Sweden) have termed genetic variation in such minute samples as microvariation or microdiversity. They established the importance of this type of variation by analyzing millimeter sized specimens from 44 cases of Wilms' tumor. All 44 patients had been treated with chemotherapy and while most recovered, a few—whose cancers demonstrated the greatest genetic variation between cells—developed metastases and died. Survival was 100% for patients lacking microdiversity.
Very few markers have been found in childhood kidney cancer that can differentiate between aggressive and less dangerous cancers. "The reason for this is that researchers have been looking for certain characteristics, such as mutations, in a single sample from each patient. However, when there is so much variation between the cells, one sample is not enough to determine the properties of the tumor," said senior author Dr. David Gisselsson, a researcher in clinical genetics at Lund University. "Tumors in children are also genetically unstable, and the greater the variation between the cells, the more malignant the cancer. The microvariation is a much better predictor of the risk of metastasis and death than the presence of individual mutations. This is an entirely new way of assessing how dangerous a tumor is."
The study was published in the January 27, 2015, online edition of the journal Nature Communications.
Related Links:
Lund University
Latest Pathology News
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
- Advances in Monkeypox Virus Diagnostics to Improve Management of Future Outbreaks
- Nanoneedle-Studded Patch Could Eliminate Painful and Invasive Biopsies
- AI Cancer Classification Tool to Drive Targeted Treatments
- AI-Powered Imaging Enables Faster Lung Disease Treatment
- New Laboratory Method Speeds Diagnosis of Rare Genetic Disease
- New Technology Autonomously Detects AI Hallucinations in Digital Pathology
- Novel Algorithm Rapidly Identifies Cell Types to Improve Cancer Diagnosis
- AI Method Speeds Up Cancer Tracking Using Blood Tests
- New AI Tool Improves Blood Cancer Diagnosis
- Novel Platform Technology Predicts Diseases by Early Detection of Aging Signals in Liver Tissue
- AI Model Detects More Than 170 Cancer Types
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more
New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
Polysialic acid is a unique acidic glycan predominantly found in brain regions associated with memory and emotion, but it is also present in the bloodstream. Research has shown that blood levels of polysialic... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read moreTechnology
view channel
Inexpensive DNA Coated Electrode Paves Way for Disposable Diagnostics
Many people around the world still lack access to affordable, easy-to-use diagnostics for diseases like cancer, HIV, and influenza. Conventional sensors, while accurate, often rely on expensive equipment... Read more
New Miniature Device to Transform Testing of Blood Cancer Treatments
Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. However, despite its promise,... Read moreIndustry
view channel
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more